Nicoya Life Sciences Expands Access to Gold-Standard SPR with Launch of Revo™ Platform
Nicoya Life Sciences, Inc., a recognized leader in advanced biophysical characterization technologies for biologics discovery and development, has announced the launch of Revo™, a next-generation, label-free binding kinetics platform designed to broaden access to high-quality surface plasmon resonance (SPR) data. Revo is purpose-built to deliver publication-ready, real-time kinetic and affinity measurements while eliminating many of the cost, complexity, and operational barriers that have historically limited SPR adoption to large, well-resourced laboratories.
SPR has long been considered the gold standard for studying biomolecular interactions, providing unparalleled insight into binding kinetics, affinity, and specificity. However, traditional SPR systems often require significant capital investment, dedicated infrastructure, and specialized expertise to operate and maintain. These requirements have placed SPR out of reach for many small and midsize research teams, including startups, academic laboratories, and translational research groups. Revo was developed to change that paradigm by delivering trusted SPR performance in a compact, user-friendly benchtop format.
The Revo™ system addresses a longstanding industry gap: the need for a biomolecular interaction analysis platform that produces reliable, high-quality data while fitting seamlessly into real-world laboratory workflows. Designed as a four-channel benchtop instrument, Revo supports measurements in complex biological media, minimizes routine maintenance, and offers a space- and cost-efficient alternative to conventional SPR platforms. By lowering both technical and financial barriers, Revo empowers more researchers to generate confident, data-driven insights earlier in drug and vaccine development.
“SPR has always delivered exceptional insight into biomolecular interactions, but access has traditionally been limited to a small subset of laboratories,” said Ryan Denomme, CEO and co-founder of Nicoya Life Sciences. “Many lower-cost or alternative label-free systems attempt to address this gap but often require compromises in data quality, automation, sample consumption, or experimental flexibility. With Revo, scientists no longer have to choose between affordability and performance. They can obtain high-quality SPR data at a fraction of the price of comparable systems, without sacrificing the capabilities that matter most.”
At the core of Revo’s innovation is the integration of digital microfluidics (DMF) with nanotechnology-based biosensors. These technologies are housed within a disposable cartridge, eliminating the need for complex tubing, pumps, and routine fluidics maintenance. This cartridge-based design not only simplifies system operation but also enhances reproducibility and reliability across experiments. Each Revo cartridge supports up to 18 total interactions and can generate as many as 90 individual binding curves per assay—comparable to the throughput of a standard 96-well plate—while maintaining the sensitivity and precision expected from SPR.
The platform offers a number of key advantages tailored to modern research environments. Revo delivers high-quality, reproducible SPR data with minimal hands-on time, enabling scientists to focus more on experimental design and interpretation rather than instrument operation. With sample volume requirements as low as 2 µL, the system helps laboratories conserve valuable or hard-to-produce reagents, which is particularly important in early-stage biologics research.
Revo is also compatible with crude and complex samples, allowing researchers to work with real-world matrices rather than highly purified systems alone. Automated sample and buffer handling—including serial dilutions—reduces manual steps and can cut hands-on time by up to 70%, improving consistency and experimental throughput. Flexible assay configurations and surface chemistries further expand the platform’s versatility, with functionalized cartridge options such as carboxyl and streptavidin surfaces supporting a wide range of biomolecular interaction studies.
Complementing the hardware is Nicoya’s comprehensive software suite, designed to simplify both assay setup and data analysis. The software provides intuitive access to kinetics, affinity, screening, and quantitation workflows, enabling researchers without specialized SPR training to confidently design experiments and interpret results. This focus on usability ensures that high-quality interaction data is accessible to a broader scientific audience, without compromising analytical rigor.
Revo has been engineered with scalability in mind. The system offers four- to eight-channel throughput configurations, making it well suited for laboratories that require robust interaction data but do not need the scale or investment associated with high-throughput screening platforms. Multiple pricing and throughput options allow customers to scale their capabilities as research programs grow, while maintaining consistency in data quality across Nicoya’s SPR offerings.
With the launch of Revo™, Nicoya Life Sciences continues its mission to advance next-generation SPR technology—not through cost-cutting alone, but through thoughtful innovation that balances performance, usability, and accessibility. By bringing gold-standard SPR capabilities to benchtop laboratories, Revo has the potential to accelerate discovery, improve decision-making, and expand the impact of biomolecular interaction analysis across the life sciences.
Source link : https://www.businesswire.com/
